Collaboration Agreements (Tables)

9 Months Ended

Sep. 30, 2016

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Revenues from Collaborations

The following table is a summary of the revenue recognized from the Company’s collaborations for the three and nine months ended September 30, 2016 and 2015:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Teva:
Recognition of upfront payment	$	—	$	2,940	$	—	$	8,724
Research funding		29		11		87		101
Genentech:
Recognition of upfront payment		—		182		157		542
Research funding		383		910		1,149		2,730
Milestone payment		—		250		—		250
Total collaboration revenue	$	412	$	4,293	$	1,393	$	12,347